-+ 0.00%
-+ 0.00%
-+ 0.00%

Citigroup Downgrades Accendra Health to Neutral, Lowers Price Target to $1.5

Benzinga·08/11/2026 12:21:03
语音播报
Citigroup analyst Daniel Grosslight downgrades Accendra Health (NYSE:ACH) from Buy to Neutral and lowers the price target from $4.5 to $1.5.